Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic protei…
$2.94-2.33%
报价 2026-11-13
市值
$112.7M
EV
–
PE (TTM)
–
预期 PE
–
52 周区间距高点 -42.7%
$2.94$5.13
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| MOLNMolecular Partners AG | $112.7M | -2.3% | – | 0% | – | – | – | |
| FHTXFoghorn Therapeutics Inc. | $124.1M | +1.0% | -18.9% | 99.1% | 29.9x | 8.0x | – | |
| ZURAZura Bio Limited | $119.4M | -13.3% | – | 0% | – | – | – | |
| CLLSCellectis S.A. | $118.9M | -11.3% | – | 74.7% | – | – | – | |
| CUECue Biopharma, Inc. | $117.1M | -7.9% | -84.6% | 99.7% | – | – | – | |
| NERVMinerva Neurosciences, Inc. | $114.6M | -3.4% | -56.2% | 0% | – | – | – | |
| VYGRVoyager Therapeutics, Inc. | $107.7M | +1.8% | +31.0% | 89.9% | – | – | – | |
| OKUROnKure Therapeutics, Inc. | $106.5M | -12.6% | -28.6% | 0% | – | – | – | |
| IMUXImmunic, Inc. | $102.6M | -3.5% | -96.9% | 0% | – | – | – | |
| 同行中位数 | – | – | -42.4% | 37.3% | 29.9x | 8.0x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
报告货币 CHF(非美元)暂无季度数据(首次研究运行后填充)。